← Back to Treatments
🏅 FDA Orphan Designation

Synribo

omacetaxine mepesuccinate

Manufacturer: IVAX International GmbH

Indicated for:
Chronic myeloid leukemiaOrphanAcute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitorOrphanAccel.

FDA-Approved Indications (2)

Chronic myeloid leukemiaOrphan Designation

Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)

Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)

Population: adults

Indications & Usage

Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)

💙 Support Programs

View all →
Synribo
IVAX International GmbH
Synribo
IVAX International GmbH

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.